Literature DB >> 2262240

The incidence of cancer among blood donors.

K Merk1, B Mattsson, A Mattsson, G Holm, B Gullbring, M Björkholm.   

Abstract

This study presents data on cancer incidence among 37,795 blood donors in an attempt to test the hypothesis that blood donation might be associated with cancer development. At a median follow-up time of nine years (range 5-13 years) a total of 1152 cancer cases have been diagnosed. The expected number of cancer cases derived from an age-matched population was 1459 giving a relative risk ratio (RR) of 0.79 (p less than 0.001). Calculations were made with and without latency periods between first blood donation and the diagnosis of cancer (0, 5, 10, 15 years). Overall, significantly decreased cancer incidence was observed (p less than 0.001) though the number of observed cases of haematological malignancies was not significantly different from that expected. For polycythaemia vera, however, the O/E ratio was 1.81 possibly indicating an association with blood donation. A more likely explanation is that this reflects increased diagnosis of polycythaemia vera in the blood donor population.

Entities:  

Mesh:

Year:  1990        PMID: 2262240     DOI: 10.1093/ije/19.3.505

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  25 in total

1.  A prospective analysis of blood donation history and risk of non-Hodgkin lymphoma.

Authors:  Kazusa Ishii; Brenda M Birmann; Xuehong Zhang; Edward Giovannucci; Kimberly A Bertrand
Journal:  Leuk Lymphoma       Date:  2015-10-16

2.  Detection of Nicotine and Nicotine Metabolites in Units of Banked Blood.

Authors:  Joesph R Wiencek; Eric A Gehrie; Amaris M Keiser; Penny C Szklarski; Kamisha L Johnson-Davis; Garrett S Booth
Journal:  Am J Clin Pathol       Date:  2019-04-02       Impact factor: 2.493

3.  Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors.

Authors:  Malin Hultcrantz; Anton Modlitba; Senthil K Vasan; Arvid Sjölander; Klaus Rostgaard; Ola Landgren; Henrik Hjalgrim; Henrik Ullum; Christian Erikstrup; Sigurdur Y Kristinsson; Gustaf Edgren
Journal:  Thromb Res       Date:  2019-12-20       Impact factor: 3.944

4.  Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.

Authors:  Malin Hultcrantz; Sigurdur Yngvi Kristinsson; Therese M-L Andersson; Ola Landgren; Sandra Eloranta; Asa Rangert Derolf; Paul W Dickman; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

Review 5.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 6.  Iron and Cancer.

Authors:  Suzy V Torti; David H Manz; Bibbin T Paul; Nicole Blanchette-Farra; Frank M Torti
Journal:  Annu Rev Nutr       Date:  2018-08-21       Impact factor: 11.848

Review 7.  The role of iron supplementation during epoietin treatment for cancer-related anemia.

Authors:  M Hedenus; G Birgegård
Journal:  Med Oncol       Date:  2008-05-13       Impact factor: 3.064

8.  Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis.

Authors:  Xiang Xue; Sadeesh K Ramakrishnan; Kevin Weisz; Daniel Triner; Liwei Xie; Durga Attili; Asha Pant; Balázs Győrffy; Mingkun Zhan; Christin Carter-Su; Karin M Hardiman; Thomas D Wang; Michael K Dame; James Varani; Dean Brenner; Eric R Fearon; Yatrik M Shah
Journal:  Cell Metab       Date:  2016-08-18       Impact factor: 27.287

9.  The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels.

Authors:  Giuseppe Tagariello; Rosanna Di Gaetano; Roberto Sartori; Daniela Zanotto; Donata Belvini; Paolo Radossi; Renzo Risato; Giovanni Roveroni; Roberta Salviato; Cristina Tassinari; Nunzio Toffano
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

Review 10.  Iron, free radicals and cancer.

Authors:  P Reizenstein
Journal:  Med Oncol Tumor Pharmacother       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.